Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The PDUFA report

The PDUFA report

WASHINGTON - The FDA last week provided to Congress its fourth annual performance report on the Prescription Drug User Fee Act of 1992 (PDUFA), and FDA Commissioner David Kessler boasted of the progress the report reflects in a valedictory address to the Food and Drug Law Institute.

In what the agency said was Kessler's last major speech as commissioner, he said the

Read the full 633 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers